Development and validation of a 14-CpG DNA methylation signature and drug targets for prognostic prediction in breast cancer
The 14-CpG model serves as a useful biomarker for predicting prognosis in BC patients. When combined with TNM staging, it offers a potential strategy for individualized clinical decision-making, guiding personalized therapeutic regimen selection for clinicians.
Authors
- Mingxiao Hou (ORCID: https://orcid.org/0000-0001-6865-7007)
- Zhongwei Yu
- Baoxing Tian (ORCID: https://orcid.org/0000-0003-1464-6817)
- Qian Chen (ORCID: https://orcid.org/0000-0001-7541-1419)
- Yuan Zhuang (ORCID: https://orcid.org/0000-0001-7825-0032)
- Yihui Gu (ORCID: https://orcid.org/0000-0002-9321-1768)
- Liping Chen (ORCID: https://orcid.org/0000-0002-5601-1302)
- Xia Qiu (ORCID: https://orcid.org/0000-0002-3694-7357)
Institutions
- Shanghai Jiao Tong University (CN)
- Tongren Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-03-19
- DOI
- https://doi.org/10.3389/fmed.2025.1548726
- Citations
- 2
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Science and Technology Commission of Shanghai Municipality